Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14920540 | 0.77 | NR1I2 (0.44) | KDM4EAPOBEC3GALDH1A1KMT2AHSD11B1 | |
| SCHEMBL3478388 | 0.77 | APOBEC3G (0.39) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL1094584 | 0.77 | APOBEC3G (0.47) | TDP1APOBEC3GALDH1A1KMT2ASCN9A | |
| SCHEMBL1093391 | 0.77 | KDM4E (0.49) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL15258645 | 0.74 | KDM4E (0.47) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL1093406 | 0.74 | KDM4E (0.47) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL1093933 | 0.73 | KDM4E (0.49) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL11505084 | 0.72 | KDM4E (0.57) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL1094120 | 0.71 | KDM4E (0.49) | KDM4ETDP1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL15258658 | 0.67 | KDM4E (0.48) | KDM4ETDP1APOBEC3GALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148992-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181797-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | KDM4E 4039/4885TDP1 2446/4885APOBEC3G 4833/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | KDM4E 4039/4885TDP1 2446/4885APOBEC3G 4833/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | KDM4E 4039/4885TDP1 2446/4885APOBEC3G 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.